🧪 Upstream processing involves culturing animal or microbial cells in different vessel types.
💧 Downstream processing removes contaminants from material harvested from a bioreactor.
🏭 Manufacturing combines active pharmaceutical ingredients with excipients for drug products.
🔬 Analytical technologies are used to characterize biological products and manufacturing processes.
💼 The biopharmaceutical industry relies on partnerships to navigate the global business environment.
Introduction:
Normalization processes in the bioprocessing industry are currently experiencing a slump, but bioprocess vendors are optimistic about a recovery in 2024.
- Normalization processes in the bioprocessing industry, such as chromatography and filtration, have slowed down due to the impact of the COVID-19 pandemic.
- This slowdown is mainly attributed to travel restrictions, reduced access to manufacturing facilities, and delays in customer projects.
- However, bioprocess vendors expect a recovery in 2024, driven by factors such as the growing demand for biopharmaceuticals and investments in new manufacturing facilities.
- The shift towards decentralized manufacturing and the adoption of single-use technologies are also expected to contribute to the recovery.
- Despite the current challenges, vendors are focusing on innovation and offering enhanced services to meet the evolving needs of the bioprocessing industry.
Conclusion:
Normalization processes in the bioprocessing industry are currently facing challenges due to the COVID-19 pandemic, but bioprocess vendors are optimistic about a recovery in 2024. They expect factors such as increased demand for biopharmaceuticals and investments in new manufacturing facilities to drive this recovery. Additionally, the adoption of decentralized manufacturing and single-use technologies is predicted to contribute to the industry’s rebound. Vendors are also prioritizing innovation and providing enhanced services to cater to the evolving needs of the bioprocessing industry.
